PAA Stock Overview
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally.
PharmAust Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.075|
|52 Week High||AU$0.12|
|52 Week Low||AU$0.065|
|1 Month Change||-7.41%|
|3 Month Change||5.63%|
|1 Year Change||-18.48%|
|3 Year Change||-50.00%|
|5 Year Change||50.00%|
|Change since IPO||-99.17%|
Recent News & Updates
Is PharmAust (ASX:PAA) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
|PAA||AU Pharmaceuticals||AU Market|
Return vs Industry: PAA exceeded the Australian Pharmaceuticals industry which returned -23.6% over the past year.
Return vs Market: PAA underperformed the Australian Market which returned -10.8% over the past year.
|PAA Average Weekly Movement||8.2%|
|Pharmaceuticals Industry Average Movement||10.7%|
|Market Average Movement||9.4%|
|10% most volatile stocks in AU Market||16.5%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: PAA is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: PAA's weekly volatility (8%) has been stable over the past year.
About the Company
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer.
PharmAust Limited Fundamentals Summary
|PAA fundamental statistics|
Is PAA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PAA income statement (TTM)|
|Cost of Revenue||AU$314.34k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0053|
|Net Profit Margin||-37.87%|
How did PAA perform over the long term?See historical performance and comparison